Desai resigns as chief of Apotex

Apotex chief executive officer and president, Jeremy Desai, has “resigned to pursue other opportunities”, with immediate effect. Jeff Watson – previously president of Global Generics – has been appointed as president and chief operating officer with responsibility for “day-to-day operations for the company on a global basis”, while vice-chairman Jack Kay will also assume the role of chief executive officer, having previously held the role before Desai’s appointment.

Apotex chief executive officer and president, Jeremy Desai, has “resigned to pursue other opportunities”, with immediate effect. Jeff Watson – previously president of Global Generics – has been appointed as president and chief operating officer with responsibility for “day-to-day operations for the company on a global basis”, while vice-chairman Jack Kay will also assume the role of chief executive officer, having previously held the role before Desai’s appointment.

An Apotex spokesman told Generics bulletin that the firm would not “violate [our] commitment to privacy” by providing details surrounding Desai’s departure

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

More from Generics Bulletin

Amgen’s Aflibercept Starts Strong As Regeneron Counts Cost Of Eylea Competition

 
• By 

Amgen told investors during its 1 May first-quarter earnings call that its Pavblu biosimilar to Eylea 2mg had flown out of the gates, while Regeneron admitted “some difficult news related to our retinal franchise.”

BGMA Becomes Medicines UK

 
• By 

The UK generics and biosimilars industry will now be represented by Medicines UK, the new name for the former British Generic Manufacturers Association.

J&J Denied Injunction Over Private-Label Ustekinumab In US

 
• By 

Stelara originator J&J has been denied in its initial attempt to prevent Samsung Bioepis and ustekinumab biosimilar partner Sandoz from selling a private-label version of the product through a PBM in the US.